Literature DB >> 11856728

Loss of p53 compensates for alpha v-integrin function in retinal neovascularization.

Staffan Strömblad1, Arun Fotedar, Howard Brickner, Chandra Theesfeld, Edith Aguilar de Diaz, Martin Friedlander, David A Cheresh.   

Abstract

alpha(v)-Integrin antagonists block neovascularization in various species, whereas 20% of alpha(v)-integrin null mice are born with many normal looking blood vessels. Given that blockade of alpha(v)-integrins during angiogenesis induces p53 activity, we utilized p53 null mice to elucidate whether loss of p53 can compensate for alpha(v)-integrin function in neovascularization of the retina. Murine retinal vascularization was inhibited by systemic administration of an alpha(v)-integrin antagonist. In contrast, mice lacking p53 were refractory to this treatment, indicating that neovascularization in normal mice depends on alpha(v)-integrin-mediated suppression of p53. Blockade of alpha(v)-integrins during neovascularization resulted in an induction of p21(CIP1) in wild type and, surprisingly, in p53 null retinas, indicating that alpha(v)-integrin ligation regulates p21(CIP1) levels in a p53-independent manner. In conclusion, we demonstrate for the first time an in vivo intracellular mechanism for compensation of integrin function and that p53 and alpha(v)-integrins act in concert during retinal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856728     DOI: 10.1074/jbc.C200044200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.

Authors:  Michael I Dorrell; Edith Aguilar; Lea Scheppke; Faith H Barnett; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

2.  Retinal angiogenesis suppression through small molecule activation of p53.

Authors:  Sai H Chavala; Younghee Kim; Laura Tudisco; Valeria Cicatiello; Till Milde; Nagaraj Kerur; Nidia Claros; Susan Yanni; Victor H Guaiquil; William W Hauswirth; John S Penn; Shahin Rafii; Sandro De Falco; Thomas C Lee; Jayakrishna Ambati
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

3.  Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis.

Authors:  Ji-Young Bang; Eung-Yoon Kim; Dong-Ku Kang; Soo-Ik Chang; Moon-Hi Han; Kwang-Hyun Baek; In-Cheol Kang
Journal:  Mol Cell Proteomics       Date:  2011-05-10       Impact factor: 5.911

4.  Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways.

Authors:  Anat Erdreich-Epstein; Linda B Tran; Orla T Cox; Elaine Y Huang; Walter E Laug; Hiroyuki Shimada; Melissa Millard
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

5.  Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen.

Authors:  Wenjie Bao; Staffan Strömblad
Journal:  J Cell Biol       Date:  2004-11-22       Impact factor: 10.539

6.  Integrin signaling is critical for pathological angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Weiyi Feng; David R Phillips; Tatiana V Byzova
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

7.  Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis.

Authors:  John D Hood; Ricardo Frausto; William B Kiosses; Martin A Schwartz; David A Cheresh
Journal:  J Cell Biol       Date:  2003-09-01       Impact factor: 10.539

Review 8.  Tiny dancers: the integrin-growth factor nexus in angiogenic signaling.

Authors:  Susan S Smyth; Cam Patterson
Journal:  J Cell Biol       Date:  2002-07-08       Impact factor: 10.539

9.  Loss of epithelial p53 and αv integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment.

Authors:  A Savar; S Acin; C L Gonzalez; T El-Sawy; O Mejia; Z Li; B Esmaeli; A Lacy-Hulbert; A K El-Naggar; J H McCarty; C Caulin
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.